Imfinzi improves survival for unresectable non-small cell lung cancer
Durvalumab appeared associated with improved OS compared with placebo among patients with unresectable stage III non-small cell lung cancer whose disease had not progressed following platinum-based chemotherapy concurrent with radiation therapy, according to interim results from the PACIFIC trial.
Durvalumab (Imfinzi; AstraZeneca, MedImmune) — a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80 — is indicated for the treatment of patients with unresectable stage III NSCLC whose disease had not progressed following concurrent platinum-based chemoradiation therapy.
The PACIFIC trial is a randomized, double-blind trial that included 713 patients with stage III unresectable NSCLC whose disease had not progressed following platinum-based chemoradiation therapy.
As HemOnc Today previously reported, durvalumab significantly extended PFS compared with placebo.
The latest data showed durvalumab significantly and clinically meaningfully improved OS compared with placebo.
“The readout of positive OS data at the interim analysis of the PACIFIC trial provides additional compelling evidence of the clinical benefit that Imfinzi can offer patients in this earlier stage of lung cancer,” Sean Bohen, executive vice president of global medicines development and chief medical officer at AstraZeneca, said in a press release. “We look forward to sharing these results with health authorities to support ongoing regulatory interactions and to update the Imfinzi label with these important data.”